Quest Diagnostics
DGX
850 hedge funds and large institutions have $13.8B invested in Quest Diagnostics in 2022 Q2 according to their latest regulatory filings, with 83 funds opening new positions, 272 increasing their positions, 312 reducing their positions, and 72 closing their positions.
81% more call options, than puts
Call options by funds: $103M | Put options by funds: $56.9M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
15% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 72
0.27% more ownership
Funds ownership: 88.05% → 88.32% (+0.27%)
0% less funds holding
Funds holding: 851 → 850 (-1)
4% less capital invested
Capital invested by funds: $14.4B → $13.8B (-$609M)
13% less repeat investments, than reductions
Existing positions increased: 272 | Existing positions reduced: 312
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$130M |
| 2 |
BlackRock
New York
|
+$86.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$78.1M |
| 4 |
Morgan Stanley
New York
|
+$56.8M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$49.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FMI
Fiduciary Management Inc
Milwaukee,
Wisconsin
|
-$225M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$163M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$82.5M |
| 4 |
Janus Henderson Group
London,
|
-$38.4M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$31.3M |
DGX Hedge Fund Activity: Q2 2022 in Review
850 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2022, worth a combined $13.8B — down 4.2% from $14.4B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new DGX positions and 72 closed out — a net gain of 11 holders — while 272 added to existing stakes and 312 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $130M. The largest seller was Fiduciary Management Inc, exiting entirely with an estimated $225M sold.
- 850 institutional investors held Quest Diagnostics (DGX) as of Q2 2022, down from 851 in Q1 2022.
- Funds reported $13.8B of Quest Diagnostics stock for Q2 2022, down 4.2% quarter-over-quarter.
- 83 funds opened new Quest Diagnostics positions in Q2 2022 and 72 closed out, a net change of +11 holders.
- The largest Quest Diagnostics buyer in Q2 2022 was T. Rowe Price Associates, an estimated $130M added.
- The largest Quest Diagnostics seller in Q2 2022 was Fiduciary Management Inc, an estimated $225M sold.
Based on aggregated 13F filings for Q2 2022.